To check the effect and safety of capsule Ocemic in Otitis Media
Phase 2
- Conditions
- Health Condition 1: H720- Central perforation of tympanic membrane
- Registration Number
- CTRI/2022/06/043609
- Lead Sponsor
- Bharati Vidyapeeth deemed to be University college of Ayurved and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Patients of having otitis media both asom and csom
2 age group between 15 to 60 years irrespective of gender and religion and socio economical class
Exclusion Criteria
1Patients with age below 15 years and above 60 years
2 recently ear operated patients
3 patients who are suffering from bleeding from ear
4 patients having CSF otorrhoea and cholesteatoma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Ocemic target in treating central perforation of the tympanic membrane?
How does Ocemic compare to standard-of-care treatments like antibiotics for acute otitis media in clinical trials?
Are there specific biomarkers that predict response to Ocemic in patients with H720 otitis media?
What are the potential adverse events associated with Ocemic and how are they managed in phase II trials?
What related compounds or combination therapies are being explored alongside Ocemic for tympanic membrane perforation treatment?